Healthcare specialist SHS Capital acquires a majority stake in Basic Pharma, a leading Dutch pharmaceutical CDMO and dossier developer for nasal sprays

PRESS RELEASE

Healthcare specialist SHS Capital acquires a majority stake in Basic Pharma, a leading Dutch pharmaceutical CDMO and dossier developer for nasal sprays

• SHS Capital has signed a binding agreement to acquire a majority stake in Basic Pharma Holding B.V., a Netherlands-based pharmaceutical developer and full-service contract development and manufacturing organisation (CDMO). The transaction is expected to close shortly
• Basic Pharma is a specialised developer and manufacturer of nasal sprays and semi-solid pharmaceuticals. Its integrated “licence & supply” model – combining in-house product development, ownership of proprietary dossiers, regulatory affairs, pharmacovigilance and GMP manufacturing – differentiates the company in the European market and ranks it among the top European nasal spray CDMOs by production capacity
• The company has grown strongly in recent years, driven by high demand for its nasal sprays, creams and newly introduced prescription products, and benefits from a highly loyal customer base of white-label and private-label distributors as well as generic pharmaceutical companies
• The investment of SHS Capital provides a structured succession solution for founder and CEO Bob Kool, who reinvests alongside SHS Capital, and aims to accelerate Basic Pharma’s next phase of growth through internationalisation, continued product development and selective buy-and-build opportunities

Tübingen / Geleen, 14 July 2026

Healthcare investor SHS Capital invests in Basic Pharma, a Dutch speciality pharmaceutical platform and full-service CDMO headquartered in Geleen. The investment provides a succession solution for the founder and aims to develop Basic Pharma into a leading European speciality pharma and dossier development platform for nasal sprays.

Founded in 2003 by pharmacist Bob Kool, Basic Pharma has evolved from a local contract manufacturer into an integrated pharmaceutical platform combining in-house product development, regulatory affairs, pharmacovigilance and GMP manufacturing at its facility in Geleen, the Netherlands, serving an international client base across prescription (Rx) and over-the-counter (OTC) pharmaceuticals as well as investigational medicinal products. A key differentiator is the company’s ability to develop, register and out-license product dossiers: under its “licence & supply” model, internally developed products are licensed to distributors and pharmaceutical partners while Basic Pharma retains exclusive manufacturing and market authorization rights, creating long-term customer relationships and strong recurring revenues. Basic Pharma holds a leading position in the Dutch nasal spray market and, thanks to its lean and highly efficient production set-up, offers its products at competitive prices, also internationally.

SHS Capital intends to accompany Basic Pharma as a growth partner in the coming years. The joint value creation plan focuses on strengthening the highly successful core business, driving operational excellence, further professionalising the organisation, and accelerating international expansion, particularly in European markets with attractive pricing dynamics. In addition, Basic Pharma is well positioned as a platform for selective buy-and-build opportunities in the fragmented European CDMO landscape. Founder Bob Kool will continue to support the company and will remain involved as a shareholder and member of the Advisory Board.

“For more than two decades, we have built Basic Pharma into an integrated pharmaceutical platform with a strong team and loyal, long-standing customers,” says Bob Kool, founder and CEO of Basic Pharma. “It was very important to me to place the succession of my life’s work in the right hands. With SHS, we have found a highly experienced and specialised healthcare private equity fund that truly understands our business, values our people and shares our ambitions. I am delighted that Basic Pharma’s next chapter will be written together with such a knowledgeable partner, and I look forward to continuing to support the company in this exciting phase.”

“Basic Pharma is exactly the type of company we look for: a specialised European healthcare champion with a differentiated business model, proprietary dossiers and significant untapped international potential,” says Dr Cornelius Maas, Partner at SHS Capital. “We look forward to supporting the team in the next phase of growth, organically and through selective acquisitions.”

About Basic Pharma

Basic Pharma Holding B.V. is a Netherlands-based pharmaceutical developer and full-service CDMO, comprising Basic Pharma Manufacturing, Basic Pharma Technologies and Interdos Pharma. The company develops, registers and manufactures prescription and OTC pharmaceuticals – including nasal sprays, creams, ointments, liquids and pre-filled syringes – as well as investigational medicinal products for clinical trials. Through Interdos Pharma, the group additionally provides regulatory affairs, pharmacovigilance, QA/QC and Qualified Person services to internal and external customers. All products are manufactured at the company’s GMP-certified facility in Geleen, the Netherlands. Basic Pharma employs more than 250 people and serves an international customer base of distributors and pharmaceutical companies across Europe.

More information at: https://basicpharma.nl/

About SHS Capital

SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. “Building European Healthcare Champions” is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 50 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI.

More information at: www.shs-capital.eu

PR contact:

Regine Hujer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstrasse 12
72072 Tuebingen
tuebingen@shs-capital.eu